The global human microbiome therapeutics market is estimated to grow at a CAGR of 60.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1bn in 2024.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 106 tables and 47 figures– all unavailable elsewhere.
The 250-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Human Microbiome Therapeutics Market forecast from 2019-2029
• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Sector:
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Diseases
• Dermatological Conditions
• Other Disorders
• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Region:
• U.S.
• EU5: Germany, France, U.K., Italy, Spain
• Japan
• Rest of the World
The human microbiome market revenue forecast 2019-2029 for the US, EU5 and Japan markets are further broken down by sector.
• This report discusses the top 20 companies in the human microbiome therapeutics market:
• 4D Pharma
• AOBiome Therapeutics
• C3J Therapeutics
• Caelus Health
• Enterome Bioscience
• Ferring Pharmaceuticals
• Finch Therapeutics/Crestovo
• IGEN BIOTECH GROUP
• Immuron
• Intrexon Corporation
• MaaT Pharma
• MatriSys Biosystem
• Microbiome Therapeutics LLC
• Osel
• Ritter Pharmaceuticals
• Second Genome
• Seres Therapeutics
• Synlogic
• Synthetic Biologics
• Vedanta Biosciences
This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products
• This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.
• Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.
• Key Questions Answered by this Report:
• How is the market for human microbiome therapeutics evolving?
• What is driving and restraining the human microbiome therapeutics market dynamics?
• What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
• How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2019 to 2029?
• Which submarkets will be the main driver of growth in the overall market from 2019 to 2029?
• How will the regional market shares in the human microbiome therapeutics market change by 2029 and which geographical region will lead the market in 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the global human microbiome therapeutics market. You find data, trends and predictions.
Buy our report today Human Microbiome Therapeutics Market Analysis: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Human Microbiome Therapeutics: Market Overview
1.2 Global Human Microbiome Therapeutics: Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Human Microbiome
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 Human Microbiota in Health
2.2.1 Microbiome-Host Interaction
2.2.2 Human Microbiota Ecosystems
2.3 Human Microbiota in Disease
2.3.1 Role of Microbiota in Health and Disease (Human Microbiota in Health)
2.4 Microbiome Projects under development
2.5 Hindrances for Microbiome as therapy
2.6 Unmet needs of Microbiome
3. The Global Burden of Human Microbiome Diseases
4. Human Microbiome Therapeutics: Market Segmentation
4.1 Gastrointestinal Disorders
4.1.1 Classification of Gastrointestinal Disorders
4.1.2 Role of Microbiota in Gastrointestinal Disorders
4.2 Infectious Disorders
4.2.1 Classification of Infectious Disease
4.2.2 Role of Microbiota in Infectious Disease
4.3 Metabolic & Liver Disorders
4.3.1 Classification of Metabolic & Liver Disorder
4.3.2 Role of Microbiota in Metabolic Disorders
4.4 Dermatological Conditions
4.4.1 Classification of Dermatological Conditions
4.4.2 Role of Microbiota in Dermatological Conditions
5. Phases of Clinical Trials
6. Human Microbiome Therapeutics: Market Definition
6.1 The Global Human Microbiome Therapeutics Market, 2019-2029
6.2 The Global Human Microbiome Therapeutics Market: Market Overview
6.3 The Global Human Microbiome Therapeutics In 2020
6.4 The Global Human Microbiome Therapeutics Market Forecast 2019-2029
6.5 Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029
7. Global Human Microbiome Therapeutics Market by Sector: Market Forecast 2019-2029
7.1 Gastrointestinal Disorders Submarket Forecast 2019-2029
7.2 Infectious Diseases Submarket Forecast 2019-2029
7.3 Metabolic Diseases Submarket Forecast 2019-2029
7.4 Dermatological Conditions Submarket Forecast 2019-2029
7.5 Other Disorders (Cardiovascular, CNS, Cancer) Submarket Forecast 2019-2029
8. Global Microbiome Therapeutics Market Potential
8.1 Microbiome Therapeutics Market Potential for GI Disorders
8.2 Microbiome Therapeutics Market Potential for Infectious Disorders
8.3 Microbiome Therapeutics Market Potential for Metabolic Disorders
8.4 Microbiome Therapeutics Market Potential for Dermatological Conditions
8.5 Microbiome Therapeutics Market Potential for Other Disorders
9. Leading National Markets for Human Microbiome Therapies: Market Forecast 2019-2029
9.1 The Human Microbiome Therapeutics Market by Region
9.1.1 Global Distribution of Human Microbiome Therapeutics, 2021
9.2 Leading National Markets: Forecast 2019-2029
9.2.1 Changing Market Shares by Region, 2019-2029
9.3 United States
9.3.1 The United States Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.3.2 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
9.3.2.1 The United States Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029
9.4 EU5
9.4.1 EU5 Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.4.1.1 EU5 Markets: Changing Market Shares by Country, 2019-2029
9.4.2 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
9.4.2.1 EU5 Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029
9.5 Germany
9.5.1 German Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.6 France
9.6.1 French Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.7 UK
9.7.1 UK Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.8 Italy
9.8.1 Italian Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.9 Spain
9.9.1 Spanish Human Microbiome Therapeutics Market: Market Forecast 2019-2029
9.10 Japan
9.10.1 The Cost of Treatment in Japan
9.10.2 Japanese Pharmaceutical Industry Regulatory Reform
9.10.3 Japanese Human Microbiome Therapeutics Market Forecast 2019-2029
9.10.4 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
9.10.4.1 Japan Human Microbiome Therapies: Changing Market Shares by Sector, 2019-2029
9.11 Rest of the World
9.11.1 Rest of the World Human Microbiome Therapeutics Market: Market Forecast 2019-2029
10. Leading Companies in the Human Microbiome Therapeutics Market, 2019-2029
10.1 4D Pharma Plc.
10.1.1 4D Pharma: Collaborations and Acquisitions
10.1.2 4D Pharma: Microbiome Drugs Development Pipeline, 2018
10.1.3 4D Pharma: Recent Developments
10.1.4 4D Pharma: Key Pipeline Products
10.2 Synthetic Biologics
10.2.1 Synthetic Biologics: Collaborations and Agreement
10.2.2 Synthetic Biologics: Drug Development Pipeline, 2018
10.2.3 Synthetic Biologics: Recent Developments
10.2.4 Synthetic Biologics Key Pipeline Products,2018
10.3 Seres Therapeutics
10.3.1 Seres Therapeutics: Collaborations and Agreement
10.3.2 Seres Therapeutics: Drug Development Pipeline, 2018
10.3.3 Seres Therapeutics: Key Pipeline Products
10.4 Ferring Pharmaceuticals
10.4.1 Ferring Pharmaceuticals: Collaborations and Agreement
10.4.2 Ferring Pharmaceuticals: Drug Development Pipeline, 2018
10.4.3 Ferring Pharmaceuticals: Key Pipeline Products, 2018
10.5 AOBiome Therapeutics
10.5.1 AOBiome Therapeutics: Collaborations and Agreement
10.5.2 AOBiome Therapeutics: Drug Development Pipeline, 2018
10.5.3. AOBiome Therapeutics: Key Pipeline Products, 2018
10.6 Osel Inc.,
10.6.1 Osel Inc: Product Development Activities
10.6.2 Osel Inc: Drug Development Pipeline, 2018
10.6.3 Osel Inc: Key Pipeline Products, 2018
10.7 Immuron Ltd
10.7.1 Immuron: Collaboration and Agreement
10.7.2 Immuron: Drug Development Pipeline, 2018
10.7.3 Immuron: Key Pipeline Products, 2018
10.8 Ritter Pharmaceuticals, Inc.
10.8.1 Ritter Pharmaceuticals: Collaboration and Agreement
10.8.2 Ritter Pharmaceuticals: Drug Development Pipeline, 2018
10.8.3 Ritter Pharmaceuticals: Key Pipeline Products, 2018
10.9 Intrexon Corporation
10.9.1 Intrexon: Collaboration and Agreement
10.9.2 Intrexon: Drug Development Pipeline, 2018
10.9.3 Intrexon: Key Pipeline Products, 2018
10.10 Synlogic
10.10.1 Synlogic: Collaborations and Agreement
10.10.2 Synlogic: Drug Development Pipeline, 2018
10.10.3 Synlogic: Key Pipeline Products, 2018
10.11 C3J Therapeutics
10.11.1 C3J Therapeutics: Product Development Activities
10.11.2 C3J Therapeutics: Drug Development Pipeline, 2018
10.11.3 C3J Therapeutics: Key Pipeline Products, 2018
10.12 Finch Therapeutics/Crestovo
10.12.1 Finch/Crestovo: Collaboration and Agreement
10.12.2 Finch/Crestovo: Drug Development Pipeline, 2018
10.12.3 Finch/Crestovo: Key Pipeline Products, 2018
10.13 MaaT Pharma
10.13.1 MaaT Pharma: Collaboration and Agreement
10.13.2 MaaT Pharma: Drug Development Pipeline, 2018
10.14 IGEN BIOTECH GROUP
10.14.1 IGEN BIOTECH: Product Development Activities
10.14.2 IGEN BIOTECH: Key Pipeline Products
10.15 MatriSys Biosystem
10.15.1 MatriSys Biosystem: Product Development Activities
10.15.2 MatriSys Biosystem: Drug Development Pipeline, 2018
10.15.3 MatriSys Biosystem: Key Pipeline Products, 2018
10.16 Second Genome
10.16.1 Second Genome: Collaboration and Agreement
10.16.2 Second Genome: Drug Development Pipeline, 2018
10.16.3 Second Genome: Key Pipeline Products, 2018
10.17 Microbiome Therapeutics LLC
10.17.1 Microbiome Therapeutics: Product Development Activities
10.17.2 Microbiome Therapeutics: Drug Development Pipeline, 2018
10.17.3 Microbiome Therapeutics: Key Pipeline Products, 2018
10.18 Caelus Health
10.18.1 Caelus Health: Collaboration and Agreement
10.18.2 Caelus Health: Drug Development Pipeline, 2018
10.18.3 Caelus Health: Key Pipeline Products, 2018
10.19 Enterome Bioscience
10.19.1 Enterome Bioscience: Drug Development Pipeline, 2018
10.19.2 Enterome Bioscience: Collaboration and Agreement
10.19.3 Enterome Bioscience: Key Pipeline Products, 2018
10.20 Vedanta Biosciences
10.20.1 Vedanta Biosciences: Collaboration and Agreement
10.20.2 Vedanta Biosciences: Drug Development Pipeline, 2018
10.20.3 Vedanta Biosciences: Key Pipeline Products, 2018
11. Gastrointestinal Disorders: Key Products, 2018
11.1 RBX2600 & RBX7455: Ferring Pharmaceuticals
11.2 SER-109, SER287 & SER-262: Seres Therapeutics
11.3 Ribaxamase & SYN-010: Synthetic Biologics
11.4 IMM-529: Immuron
11.5 SGM-1019: Second Genome
11.6 Blautix, Thetanix & Rosburix: 4D Pharma
11.7 EB8018: Enterome Bioscience
12. Metabolic Disorders: Key Products, 2018
12.1 RP-G28: Ritter Pharmaceuticals
12.2 IMM-124E: Immuron
12.3 CP-001: Caelus Health
12.4 NM504 & NM505: Microbiome Therapeutics
12.5 SYNB1020: Synlogic
13. Infectious Diseases: Key Products, 2018
13.1 LACTIN-V: Osel
13.2 AOB-201: AOBiome Therapeutics
13.3 MaaT001: MaaT Pharma
13.4 CBM588: Osel Inc.
14. Dermatological Disorders: Key Products, 2018
14.1 AOB101, AOB102 & AOB103: AOBiome Therapeutics
14.2 MSB-01 & MSB-03: MatriSys Biosystem
15. Other Disorders: Key Products, 2018
15.1 AG013: Intrexon
15.2 AOB202 & AOB 203: AOBiome Therapeutics
15.3 C16G2: C3J Therapeutics
15.4 Microbiome Modulators: IGEN BIOTECH
16. Qualitative Analysis of the Human Microbiome Therapeutics, 2019-2029
16.1 Market Factors Influencing Human Microbiome Therapeutics Market
16.2 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029
16.2.1 Strengths
16.2.1.1 Novel & Efficient Therapies
16.2.1.2 A Healthy R&D Pipeline
16.2.1.3 Collaboration Among Key Industry Players
16.2.2 Weaknesses
16.2.2.1 Market Competition
16.2.2.2 Consumer Perception
16.2.2.3 Ethical Issues
16.2.2.4 R&D Capabilities
16.2.2.5 Knowledge Gaps
16.2.3 Opportunities
16.2.3.1 Growing Patient Pool
16.2.3.2 Unmet Clinical Needs in Several Disease Areas
16.2.3.3 Label Expansion
16.2.3.4 Economic Growth in Emerging Market Provide Opportunity for Expansion
16.2.4 Threats
16.2.4.1 Capital Intensive Research
16.2.4.2 Regulatory Approval
16.2.4.3 Price
16.2.4.4 Intellectual Property
17. Conclusions
17.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
17.2 Leading Sectors in Human Microbiome Therapeutics in 2020
17.3 Leading Regions in the Human Microbiome Therapeutics Market in 2020
17.4 What Does the Future Hold for Microbiome Therapeutics?
Appendices
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 4.1 Skin Disease and Related Microbiota
Table 5.1 Clinical Trial Phases
Table 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020
Table 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Table 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector
Table 6.4 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020, 2024, 2029
Table 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029
Table 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029
Table 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029
Table 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m, AGR% and CAGR%), 2019-2029
Table 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029
Table 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) and Market Share (%) by Region, 2021
Table 9.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029
Table 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
Table 9.4 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021, 2024, and 2029
Table 9.5 The US Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.6 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.7 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Table 9.8 The United States Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
Table 9.9 EU5 Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2019-2029
Table 9.10 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
Table 9.11 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2019-2029
Table 9.12 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2029
Table 9.13 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Table 9.14 EU5 Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
Table 9.15 German Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2021-2029
Table 9.16 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.17 The French Human Microbiome Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.18 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.19 The UK Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.20 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.21 Italian Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.22 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.23 Spanish Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.24 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.25 Japanese Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.26 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 9.27 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Table 9.28 Japan Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
Table 9.29 The Rest of the World Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
Table 9.30 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
Table 10.1 Pipeline Therapeutics by Companies
Table 10.2 4D Pharma: Company Overview, 2018
Table 10.3 4D Pharma: Key Pipeline Products, 2018
Table 10.4 Synthetic Biologics: Company Overview, 2018
Table 10.5 Synthetic Biologics: Key Pipeline Products, 2018
Table 10.6 Seres Therapeutics: Company Overview, 2018
Table 10.7 Clinical Trials Description
Table 10.8: Clinical Trials Description
Table 10.9 Clinical Trials Description
Table 10.10 Seres Therapeutics: Key Pipeline Products, 2018
Table 10.11 Ferring Pharmaceuticals: Company Overview, 2018
Table 10.12 Clinical Trials Description
Table 10.13 Clinical Trials Description
Table 10.14 Ferring Pharmaceuticals: Key Pipeline Products, 2018
Table 10.15 AOBiome, LLC: Company Overview, 2018
Table 10.16 Clinical Trials Description
Table 10.17 AOBiome Therapeutics: Key Pipeline Products, 2018
Table 10.18 Osel Inc: Company Overview, 2018
Table 10.19 Clinical Trials Description
Table 10.20 Osel Inc: Key Pipeline Products, 2018
Table 10.21 Immuron Ltd: Company Overview, 2018
Table 10.22 Clinical Trials Description
Table 10.23 Clinical Trials Description
Table 10.24 Key Pipeline Products, 2018
Table 10.25 Ritter Pharmaceuticals, Inc.: Company Overview, 2018
Table 10.26 Clinical Trials Description
Table 10.27 Ritter Pharmaceuticals: Key Pipeline Products, 2018
Table 10.28 Intrexon Corporation: Company Overview, 2018
Table 10.29 Clinical Trials Description
Table 10.30 Intrexon: Key Pipeline Products, 2018
Table 10.31 Synlogic: Company Overview, 2018
Table 10.32 Synlogic: Key Pipeline Products, 2018
Table 10.33 C3J Therapeutics: Company Overview, 2018
Table 10.34 Clinical Trials Description
Table 10.35 C3J Therapeutics: Key Pipeline Products, 2018
Table 10.36 Finch Therapeutics: Company Overview, 2018
Table 10.37 Clinical Trials Description
Table 10.38 Finch/Crestovo: Key Pipeline Products, 2018
Table 10.39 MaaT Pharma: Company Overview, 2018
Table 10.40 Clinical Trials Description
Table 10.41 IGEN BIOTECH GROUP: Company Overview, 2018
Table 10.42 IGEN BIOTECH: Key Pipeline Products
Table 10.43 MatriSys Biosystem: Company Overview, 2018
Table 10.44 MatriSys Biosystem: Key Pipeline Products, 2018
Table 10.45 Second Genome: Company Overview, 2018
Table 10.46 Second Genome: Key Pipeline Products, 2018
Table 10.47 Microbiome Therapeutics: Company Overview, 2018
Table 10.48 Clinical Trials Description
Table 10.49 Microbiome Therapeutics: Key Pipeline Products, 2018
Table 10.50 Caelus Health: Company Overview, 2018
Table 10.51 Key Pipeline Products, 2018
Table 10.52 Enterome Bioscience: Company Overview, 2018
Table 10.53 Clinical Trials Description
Table 10.54 Enterome Bioscience: Key Pipeline Products, 2018
Table 10.55 Vedanta Biosciences: Company Overview, 2018
Table 10.56 Vedanta Biosciences: Key Pipeline Products, 2018
Table 11.1 Gastrointestinal Disorders Drugs Pipeline: Key Drugs, 2018
Table 12.1 Metabolic Disorders Drugs Pipeline, 2018
Table 13.1 Infectious Disease Drugs Pipeline: Key Products, 2018
Table 14.1 Dermatological Disorders Drugs Pipeline: Key Products, 2018
Table 15.1 Other Disorders Drugs Pipeline: Key Products, 2018
Table 16.1 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029
Table 16.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
Table 17.1 Global Human Microbiome Therapeutics: Market Forecast ($m, CAGR%), 2020, 2024 and 2029
Table 17.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020, 2024, 2029
List of Figures
Figure 1.1 Global Human Microbiome Therapeutics Market: Market Sectors
Figure 2.1 Role of Human Microbiota in Various Diseases
Figure 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) by Sector, 2020
Figure 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector, 2024-2029
Figure 6.4 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2020
Figure 6.5 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 6.6 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
Figure 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m), 2019-2029
Figure 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m), 2019-2029
Figure 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m), 2019-2029
Figure 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m), 2019-2029
Figure 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m), 2019-2029
Figure 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) by Region, 2021
Figure 9.2 US, EU, Japan and ROW Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
Figure 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
Figure 9.4 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2024-2029
Figure 9.5 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2029
Figure 9.6 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021
Figure 9.7 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2024
Figure 9.8 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2029
Figure 9.9 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 9.10 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Figure 9.11 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.12 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.13 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
Figure 9.14 EU5 Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
Figure 9.15 Germany, France, UK, Italy, and Spain Human Microbiome Drugs Market: Market Forecast ($m), 2019-2029
Figure 9.16 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
Figure 9.17 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
Figure 9.18 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2029
Figure 9.19 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Figure 19.20 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 19.21 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 19.22 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
Figure 9.23 German Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
Figure 9.24 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 9.25 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 9.26 Italian Human Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 9.27 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
Figure 9.28 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
Figure 9.29 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
Figure 9.30 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.31 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
Figure 9.32 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
Figure 17.1 Global Human Microbiome Therapeutics: Market Forecast ($m), 2019- 2029
Figure 17.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2019-2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
